Radiprodil in Participants With Hepatic Impairment

Inclusion Criteria: * Male or female participants aged 18 to 75 years, inclusive, at Screening. * Body mass index (BMI) within the range specified in the protocol. * Participants with hepatic impairment must have stable mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or severe (Child-Pugh Class C) hepatic impairment, as applicable to cohort assignment. * Healthy participants must be medically healthy with no clinically significant abnormalities as determined by the investigator. * Participants must be willing and able to comply with all study procedures and confinement requirements. * Participants of childbearing potential must agree to use highly effective contraception methods as defined in the protocol. * Participants must provide written informed consent prior to any study procedures Exclusion Criteria: * History or presence of clinically significant medical conditions that could interfere with study participation or interpretation of results. * Positive test for drugs of abuse, alcohol, or cotinine (where applicable) at Screening or check-in. * Positive serology for HIV, hepatitis B surface antigen, or hepatitis C virus. * Clinically significant abnormal laboratory values, vital signs, or ECG findings at Screening or Day -1, as judged by the investigator. * Use of prohibited concomitant medications or substances that may interfere with radiprodil metabolism. * Pregnant or breastfeeding women. * Participation in another clinical study or receipt of an investigational product within the protocol-specified timeframe prior to dosing. * Any condition that, in the opinion of the investigator or sponsor, would make participation not in the best interest of the participant or could confound study results.